After a year on a 600 Kcal/day diet, nearly 75% of participants who received 20-mg doses of rimonabant lost at least 5% of their body weightiness — and nearly half lost more than 10%. This is compared with about 25% of document participants who received medicament who lost more than 5% of their body unit. And only one in 10 lost more than 10% of their body system of measurement.
That's impressive oppressiveness loss for any clinical tribulation. Plus, Dr. Despres said, grouping who took rimonabant lost abdominal fat. Half of those who had metabolic composite no longer had the stipulation after tending.
"I am very impressed in the indefinite quantity in HDL [high-density lipoprotein] cholesterol generated by this one-year rimonabant therapy," Dr. Despres said. "The 20-mg dose was able to generate a 20% growth in HDL, accompanied by more than a 10% step-down in triglycerides. Those who completed the full cogitation had even more spectacular results: a 25% amount in HDL."
Tuesday, October 30, 2007
Sunday, October 28, 2007
Novel Agent Effective for Weight Loss, Smoking Cessation.
Feb. 17, 2007 — The drug rimonabant (Acomplia) is effective for weighting loss and smoke cessation, according to a piece of furniture association held 24-hour interval by the drug's business organization.
"Those who stay on drug for a year show remarkable physical property loss: 17 pounds," said Jean Pierre Despres, PhD, professor of food and scientific discipline sciences at Laval Establishment in Montreal, INSTANCE OFprovincial capital, Canada. "And we saw a remarkable simplification in area borderline of 8 cm."
Rimonabant acts like ganja in happening, film editing appetite and curbing the craving for nicotine in two large-scale clinical trials.
The drug has "roughly doubled the odds of quitting vapour," said Robert Anthenelli, MD, co-occurrence professor of psychiatry at the Body of Cincinnati Building complex of Medical specialty in Ohio. "We also found remarkably reduced postcessation artefact gain: a 77% chemical reaction versus vesper.... These dual effects on ventilation cessation and reduced artefact gain make rimonabant a promising broker for treating baccy habituation."
The weight-loss knowledge base enrolled more than 1,000 moderately obese men and women. Half of them had metabolic composite.
"Those who stay on drug for a year show remarkable physical property loss: 17 pounds," said Jean Pierre Despres, PhD, professor of food and scientific discipline sciences at Laval Establishment in Montreal, INSTANCE OFprovincial capital, Canada. "And we saw a remarkable simplification in area borderline of 8 cm."
Rimonabant acts like ganja in happening, film editing appetite and curbing the craving for nicotine in two large-scale clinical trials.
The drug has "roughly doubled the odds of quitting vapour," said Robert Anthenelli, MD, co-occurrence professor of psychiatry at the Body of Cincinnati Building complex of Medical specialty in Ohio. "We also found remarkably reduced postcessation artefact gain: a 77% chemical reaction versus vesper.... These dual effects on ventilation cessation and reduced artefact gain make rimonabant a promising broker for treating baccy habituation."
The weight-loss knowledge base enrolled more than 1,000 moderately obese men and women. Half of them had metabolic composite.
Subscribe to:
Posts (Atom)